Schizophrenia, Paranoid: Clinical Trials

5 trials for Schizophrenia, Paranoid, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed. 5 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 45Completed 5

Follow Schizophrenia, Paranoid: new trials by email Literature Review of Schizophrenia, Paranoid trials Research Report on Schizophrenia, Paranoid

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Research Into Antipsychotic Discontinuation and Reduction Trial
Antipsychotic Reduction, Antipsychotic Maintenance - Schizophrenia, Schizoaffective Disorder
Phase 4CompletedUniversity College, London2532016-03-242022-05-23
D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions
D-Cycloserine, Placebo, Cognitive Behavioral Therapy - Schizophrenia, Schizoaffective Disorder
Phase 4CompletedNYU Langone Health582014-02-012020-03-25
Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH)
agomelatine - Schizophrenia, Schizoaffective Disorder
Phase 4CompletedCentral Institute of Mental Health, Mannheim272013-01-012018-03-08
Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia
D-cycloserine, Cognitive Behavioral Therapy - Schizophrenia
Phase 4CompletedMassachusetts General Hospital212006-09-012017-12-19
A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis
Ziprasidone - Schizophrenia, Mania
Phase 4CompletedPfizer's Upjohn has merged with Mylan to form Viatris Inc.892003-07-012021-02-21

Narrower conditions

Schizophrenia (5)  ·  Psychotic Disorders (3)  ·  Delusions (1)  ·  Depression (1)  ·  Mania (1)

Broader conditions

Mental Disorders (5)  ·  Schizophrenia Spectrum and Other Psychotic Disorders (5)  ·  Behavior (2)  ·  Behavioral Symptoms (2)  ·  Nervous System Diseases (1)  ·  Neurobehavioral Manifestations (1)  ·  Neurologic Manifestations (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Signs and Symptoms (1)

Interventions

Cognitive Behavioral Therapy (2)  ·  Cycloserine (2)  ·  Sugars (1)  ·  agomelatine (1)  ·  ziprasidone (1)

Sponsors

Central Institute of Mental Health, Mannheim (1)  ·  Massachusetts General Hospital (1)  ·  NYU Langone Health (1)  ·  Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1)  ·  University College, London (1)

Countries

United States (2)  ·  Brazil (1)  ·  Germany (1)  ·  United Kingdom (1)

Top investigators

Donald C Goff, MD (1)  ·  Donald C. Goff, MD (1)  ·  Joanna Moncrieff, MBBS (1)  ·  Mathias Zink, MD (1)

Results publications

PMID 21723096, PMID 37778356

NIH funding

P50MH060450 (1)